Did you know that The Center for Cancer conducts clinical trials?
A clinical trial is a research study that is designed to determine if a new drug or treatment will work on a disease or will potentially be beneficial to patients. Clinical trials allow doctors and researchers to gain information on the benefits, side effects, and possible new treatments for a particular disease. It also creates alternative therapies that may not otherwise be available to patients.
Regional cancer centers, national cancer research groups, and pharmaceutical companies have designated The Center for Cancer as a clinical research site. We conduct multiple phase II-IV clinical trials in the therapeutic and supportive care areas of Oncology and Hematology.
The Center for Cancer's Clinical Trials team is comprised of physicians, nurses, study coordinators, pharmacy, laboratory technicians and other dedicated staff members. Our group of clinical research personnel is committed to providing patients with the latest developments in disease treatment and management.
For more information, please ask your doctor or call us at 856-424-3311 and ask to speak with anyone in the Clinical Trials Department.
BREAST
Extended Adjuvant: Neratinib in node positive Her2+ following Herceptin
2nd (or more) line Metastatic: TDMI vs. Xeloda prior Taxane required
HOG BRE09-146: PARP Inhibition after pre-op chemo in triple negative or BRCA positive patients
Supportive: Metastatic to bone - Zometa q4 vs q12 weeks (must have received at least 9 doses of Zometa within the previous 10-15 months
LUNG
2nd line Extensive Stage - Small Cell: Single arm open label allosteric Eg5 inhibitor
COLORECTAL
1st line MCRC: mFolfox/Bev vs Folfiri/Bev with biomarker stratification for previously untreated MCRC. Adjyvan therapy must be > 12months
2nd line Metastatic:FOLFIRI +/- Ramucirumab following 1st line FOLFOX /Bev
OVARIAN
1st line: Farletuzumab with Carbo/Taxane for platinum sensitive in first relapse
PANCREATIC
CA046: Weekly ABI-007 + Gemzar vs Gemzar alone in patiens with metastatic ademenocarcinoma of the pancreas
CLL
Adjuvant: ABT-263 with Rituxan previously untreated with B-cell CLL
REGISTRIES
Connect Multiple Myeloma: newly diagnosed requiring treatment within 2 months
Connect CLL: Plan to initiate therapy within 2 months of enrollment
SUPPORT TRIAL
DIREG VTE:A prospective, non-interventional, cohort survey on VTE risk in patients receiving new chemotherapy for locally advanced or metastatic cancer.Colorectal, NSCLC or SCLC only